Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Brazil

Brazil

The revenue in the Other Vaccines market in Brazil is projected to reach €0.85bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 11.12%, leading to a market volume of €1.44bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €22,940.00m in 2024.
Brazil is experiencing an increasing demand for other vaccines due to a growing awareness of the importance of preventive healthcare.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Other Vaccines market in Brazil has been developing at a steady pace in recent years. Brazil is known for its large population and diverse healthcare system, which has contributed to the growth of the Other Vaccines market in the country.

Customer preferences: Brazilian customers prefer vaccines that are effective, safe, and affordable. They also prioritize vaccines that are easily accessible and available in public health clinics. In addition, there is a growing trend towards the use of combination vaccines, which offer protection against multiple diseases in a single shot.

Trends in the market: One of the main trends in the Other Vaccines market in Brazil is the increasing demand for vaccines that protect against diseases such as HPV, meningococcal disease, and pneumococcal disease. This is due to the high incidence of these diseases in the country, as well as the growing awareness of the importance of vaccination.Another trend in the market is the development of new vaccines that offer protection against emerging diseases. For example, there has been a recent increase in the development of vaccines for diseases such as Zika virus and Chikungunya fever, which are prevalent in Brazil.

Local special circumstances: Brazil has a unique healthcare system that is characterized by a mix of public and private providers. The public health system, known as the Unified Health System (SUS), provides free healthcare to all Brazilian citizens, while the private sector serves those who can afford to pay for healthcare.

Underlying macroeconomic factors: Brazil is the largest economy in Latin America and has a large and growing middle class. This has contributed to the growth of the healthcare sector, including the Other Vaccines market. In addition, the Brazilian government has implemented several initiatives to increase vaccination rates in the country, which has also contributed to the growth of the market. However, the country has faced economic and political challenges in recent years, which have had an impact on the healthcare sector. Despite these challenges, the Other Vaccines market in Brazil is expected to continue to grow in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.